ClinicalTrials.gg
CompletedNCT06505031Updated Jul 16, 2026Results posted

A Study of TAK-861 in People With Narcolepsy Type 1

A Phase 3 interventional study of TAK-861 and Placebo in Narcolepsy Type 1, sponsored by Takeda. Completed at 28 sites in 11 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Narcolepsy by Takeda — 4 open to participants now, 6 under way, 2 of them phase 3. Narcolepsy · Takeda.

Enrollment
4th of 12
105 · median 95
Started
2024
with 1 other
Phase 3
3 of 16
none open now
Registered
11th of 16
by date

Among the 16 studies in Narcolepsy by Takeda, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 in phase 3, and was the 11th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

4 of the 16 studies in Narcolepsy by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Narcolepsy by Takeda, or all of them as a file.
02

Study summary

The main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment. Other aims are to learn how effective TAK-861 is in lowering the number of sudden, unexpected attacks of muscle weakness while staying conscious (cataplexy) in a week; to learn the effect TAK-861 has on participants' ability to maintain attention, participant's overall quality of life, the spectrum of narcolepsy symptoms and daily life functions; and to learn about the safety of TAK-861.

Read the detailed description

The drug being tested in this study is called TAK-861. TAK-861 is being tested to evaluate its efficacy and safety in participants with narcolepsy with cataplexy (narcolepsy type 1 [NT1]).

The study will enroll approximately 93 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:

  1. TAK-861
  2. Placebo

The study drug will be administered for 12 weeks. This multi-center trial will be conducted globally.

03

Conditions studied

  • Narcolepsy Type 1

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant has a (BMI) within the range 18 to 40 kilograms per meter square (kg/m\^2).
  2. The participant has an International Classification of Sleep Disorders, Third Edition (ICSD-3) or International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR) diagnosis of NT1.
  3. The participant has greater than or equal to (≥)4 partial or complete episodes of cataplexy/week (WCR).
  4. The participant is positive for the human leukocyte antigen (HLA) genotype HLA-DQB1*06:02 or results from radioimmunoassay indicate the participant's cerebrospinal fluid (CSF) orexin (OX)/hypocretin-1 concentration is less than or equal to (≤)110 picograms per milliliter (pg/mL) [or less than one-third of the mean values obtained in normal participants within the same standardized assay].

Exclusion criteria

Exclusion Criteria:

  1. The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with EDS.
  2. The participant: (a) has a history of myocardial infarction; (b) has a history of hepatic disease, thyroid disease, coronary artery disease, cardiac rhythm abnormality or heart failure; or (c) has any medical condition (such as unstable cardiovascular, pulmonary, renal or gastrointestinal disease).
  3. The participant has current or recent (within 6 months) gastrointestinal disease that is expected to influence the absorption of drugs.
  4. The participant has a history of cancer in the past 5 years.
  5. The participant has a clinically significant history of head injury or head trauma.
  6. The participant has a history of epilepsy, seizure, or convulsion.
  7. The participant has any current unstable psychiatric disorder or current active major depressive episode (MDE) or an active MDE in the past 6 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
105 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received oveporexton matching placebo tablets, orally, twice daily (BID) for 12 weeks.

    Drug: Placebo

  • Experimental
    TAK-861

    Participants received oveporexton tablets, 2 milligrams (mg), orally, BID for 12 weeks.

    Drug: TAK-861

Interventions

  • Oral tablet.

  • DrugPlacebo

    TAK-861-matching placebo tablet.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake Trials

    The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions (trials) done 2 hours apart. Sleep latency in each session was recorded. Participants were required to stay awake in between the four sessions. A positive change from baseline indicates an improvement. The linear MMRM was used for analysis.

    Time frame: Baseline, Week 12

  2. Change From Baseline to Week 12 in ESS Total Score

    The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness. A negative change from baseline indicates an improvement. The linear mixed effects model for repeated measures (MMRM) was used for analysis.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Weekly Cataplexy Rate (WCR) at Week 12

    Participants completed a daily participant-reported cataplexy diary to record self-reported episodes of cataplexy attacks. WCR = (total number of cataplexy attacks over a number of non-missing diary days for a given period/number of non-missing diary days in that period) \* 7. The generalized estimating equations (GEE) model was used for analysis. Reported here is the estimated mean of incidence rate with a 95 percent (%) confidence interval (CI).

    Time frame: Week 12

  2. Change From Baseline to Week 12 in Mean Number of Lapses on the Psychomotor Vigilance Test (PVT)

    The PVT is a simple reaction performance task that aims to measure sustained attention. The mean number of lapses (delayed responses to a visual cue from intraday sessions) from the two 10-minute intraday sessions was used as a measure of objective sustained attention. A negative change from baseline indicates an improvement. A constrained Longitudinal Data Analysis (cLDA) model was used to analyze the mean number of lapses and to estimate change from baseline at each visit.

    Time frame: Baseline, Week 12

  3. Proportion of Participants With Improved Patient Global Impression of Change (PGI-C) Score at Week 12

    The PGI-C is a participant self-rated scale to assess change in daytime sleepiness and overall narcolepsy symptoms. The PGI-C includes 7 items being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change. Responders were the participants reporting "1=very much improved" or "2=much improved" on PGI-C. Responder rate (proportion of participants who were responders) was estimated using a GEE model.

    Time frame: Week 12

  4. Change From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score

    The NSS-CT is a 15-item self-administered questionnaire that assesses the severity and consequences of the 5 major narcolepsy symptoms such as daytime sleepiness, cataplexy, hallucinations, sleep paralysis, and disturbed nighttime sleep (DNS) with a total score range of 0 to 57 (sum of 6 items that assess symptoms severity are rated using a six-point Likert scale \[0-5\] and 9 items that describe the symptom effect on daily life are rated using a four-point Likert scale \[0-3\]). Higher total scores mean a worse outcome. A negative change from baseline indicates an improvement. The linear MMRM was used for analysis.

    Time frame: Baseline, Week 12

  5. Change From Baseline to Week 12 in Functional Impacts of Narcolepsy Instrument (FINI) Domain Scores

    The FINI measures the functional impacts of narcolepsy across 6 domains Tiredness (items 1-7), Cognitive Functioning (items 8-12), Cataplexy (items 13-17), Social Activities (items 18-21), Everyday Activities (items 22-25), and Everyday Responsibilities (items 26-28). Each item asks about the impact that narcolepsy has had on their daily functioning during the past 7 days, and is scored from 0 to 4, where 0 indicates the best health and 4 the worst. An average score is calculated for each domain and then standardized to a 0-100 scale, where 0 indicates the best health and 100 the worst health. Standardized score = average score/4 × 100. A negative change from baseline indicates and improvement. The linear MMRM was used for analysis.

    Time frame: Baseline, Week 12

  6. Change From Baseline to Week 12 in Short Form-36 Survey (SF-36) Mental and Physical Component Scores

    The SF-36 is a 36-item, participant-reported survey of participant health that assesses the quality of life and includes both physical and mental components. It consists of 8 scaled scores (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health), which contribute variably to the physical and mental component summary scores. The component summary is scored based on a normal value of 50 based on US population average, with a normative range considered from 45-55. The lower the score the more disability. A positive change from baseline indicates an improvement, and a change greater than 3 points is considered minimally clinically meaningful. The linear MMRM was used for analysis.

    Time frame: Baseline, Week 12

  7. Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.

    Time frame: Up to 16 weeks

07

Results

Posted Jul 16, 2026

Participant flow

Participants took part in the study at various investigative sites globally from 08 October 2024 to 04 June 2025.

Participant flow — Overall Study
MilestonePlaceboOveporexton
Started3570
Completed3466
Not completed14
Withdrew: Withdrawal by subject11
Withdrew: Adverse event02
Withdrew: Reason not specified01

Outcome measures

PrimaryChange From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake Trials

The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions (trials) done 2 hours apart. Sleep latency in each session was recorded. Participants were required to stay awake in between the four sessions. A positive change from baseline indicates an improvement. The linear MMRM was used for analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · minutes
Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake Trials
minutesPlaceboOveporexton
Change From Baseline to Week 12 in Mean Sleep Latency From the Maintenance of Wakefulness Test (MWT) Wake Trials-1.01 ± 1.52919.09 ± 1.254
Statistical analysis
  • Placebo vs Oveporexton · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: 20.09 · 95% CI 16.57 to 23.61
PrimaryChange From Baseline to Week 12 in ESS Total Score

The ESS provides individuals with 8 different situations of daily life and asks them how likely they are to fall asleep in those situations (scored 0 to 3) and to try to imagine their likelihood of dozing even if they have not actually been in the identical situation; the scores are summed to give an overall score of 0 to 24. Higher scores indicate stronger subjective daytime sleepiness. A negative change from baseline indicates an improvement. The linear mixed effects model for repeated measures (MMRM) was used for analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in ESS Total Score
score on a scalePlaceboOveporexton
Change From Baseline to Week 12 in ESS Total Score-1.57 ± 0.676-11.10 ± 0.550
Statistical analysis
  • Placebo vs Oveporexton · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Least square (ls) mean difference: -9.53 · 95% CI -11.10 to -7.97
SecondaryWeekly Cataplexy Rate (WCR) at Week 12

Participants completed a daily participant-reported cataplexy diary to record self-reported episodes of cataplexy attacks. WCR = (total number of cataplexy attacks over a number of non-missing diary days for a given period/number of non-missing diary days in that period) \* 7. The generalized estimating equations (GEE) model was used for analysis. Reported here is the estimated mean of incidence rate with a 95 percent (%) confidence interval (CI).

Time frame:
Week 12
Reported as:
Mean · cataplexy attacks per week
Weekly Cataplexy Rate (WCR) at Week 12
cataplexy attacks per weekPlaceboOveporexton
Weekly Cataplexy Rate (WCR) at Week 1224.43 (16.83 to 35.46)6.12 (4.44 to 8.42)
Statistical analysis
  • Placebo vs Oveporexton · GEE · p = <0.001 (This analysis used GEE model) · Incidence rate ratio (irr): 0.25 · 95% CI 0.15 to 0.42Incidence Rate Ratio compares the incidence rate of Oveporexton vs. Placebo.
SecondaryChange From Baseline to Week 12 in Mean Number of Lapses on the Psychomotor Vigilance Test (PVT)

The PVT is a simple reaction performance task that aims to measure sustained attention. The mean number of lapses (delayed responses to a visual cue from intraday sessions) from the two 10-minute intraday sessions was used as a measure of objective sustained attention. A negative change from baseline indicates an improvement. A constrained Longitudinal Data Analysis (cLDA) model was used to analyze the mean number of lapses and to estimate change from baseline at each visit.

Time frame:
Baseline, Week 12
Reported as:
Mean · number of lapses
Change From Baseline to Week 12 in Mean Number of Lapses on the Psychomotor Vigilance Test (PVT)
number of lapsesPlaceboOveporexton
Change From Baseline to Week 12 in Mean Number of Lapses on the Psychomotor Vigilance Test (PVT)3.36 (-0.17 to 6.89)-5.46 (-7.45 to -3.46)
Statistical analysis
  • Placebo vs Oveporexton · cLDA · p = <0.001 · Mean difference (net): -8.82 · 95% CI -12.70 to -4.94
SecondaryProportion of Participants With Improved Patient Global Impression of Change (PGI-C) Score at Week 12

The PGI-C is a participant self-rated scale to assess change in daytime sleepiness and overall narcolepsy symptoms. The PGI-C includes 7 items being scored from 1 (best outcome) to 7 (worst outcome) with 4 being no change. Responders were the participants reporting "1=very much improved" or "2=much improved" on PGI-C. Responder rate (proportion of participants who were responders) was estimated using a GEE model.

Time frame:
Week 12
Reported as:
Number · proportion of participants
Proportion of Participants With Improved Patient Global Impression of Change (PGI-C) Score at Week 12
proportion of participantsPlaceboOveporexton
Proportion of Participants With Improved Patient Global Impression of Change (PGI-C) Score at Week 120.15 (0.02 to 0.27)0.90 (0.82 to 0.97)
Statistical analysis
  • Placebo vs Oveporexton · GEE · p = <0.001 (This analysis used GEE model.) · Odds ratio (or): 51.21 · 95% CI 14.14 to 185.42The odds ratio compares the odds of being a responder between oveporexton and placebo.
SecondaryChange From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score

The NSS-CT is a 15-item self-administered questionnaire that assesses the severity and consequences of the 5 major narcolepsy symptoms such as daytime sleepiness, cataplexy, hallucinations, sleep paralysis, and disturbed nighttime sleep (DNS) with a total score range of 0 to 57 (sum of 6 items that assess symptoms severity are rated using a six-point Likert scale \[0-5\] and 9 items that describe the symptom effect on daily life are rated using a four-point Likert scale \[0-3\]). Higher total scores mean a worse outcome. A negative change from baseline indicates an improvement. The linear MMRM was used for analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score
score on a scalePlaceboOveporexton
Change From Baseline to Week 12 in Narcolepsy Severity Scale for Clinical Trials (NSS-CT) Total Score-3.04 ± 1.367-21.15 ± 1.090
Statistical analysis
  • Placebo vs Oveporexton · MMRM · p = <0.001 (The analysis used a linear MMRM) · Ls mean difference: -18.11 · 95% CI -21.25 to -14.96
SecondaryChange From Baseline to Week 12 in Functional Impacts of Narcolepsy Instrument (FINI) Domain Scores

The FINI measures the functional impacts of narcolepsy across 6 domains Tiredness (items 1-7), Cognitive Functioning (items 8-12), Cataplexy (items 13-17), Social Activities (items 18-21), Everyday Activities (items 22-25), and Everyday Responsibilities (items 26-28). Each item asks about the impact that narcolepsy has had on their daily functioning during the past 7 days, and is scored from 0 to 4, where 0 indicates the best health and 4 the worst. An average score is calculated for each domain and then standardized to a 0-100 scale, where 0 indicates the best health and 100 the worst health. Standardized score = average score/4 × 100. A negative change from baseline indicates and improvement. The linear MMRM was used for analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Functional Impacts of Narcolepsy Instrument (FINI) Domain Scores
score on a scalePlaceboOveporexton
Tiredness: Week 12-4.32 ± 3.410-45.09 ± 2.822
Cognitive Functioning: Week 12-3.56 ± 3.586-33.74 ± 2.835
Cataplexy: Week 12-5.53 ± 3.028-24.63 ± 2.484
Social Activities: Week 120.05 ± 3.769-36.06 ± 3.009
Everyday Activities: Week 12-6.66 ± 3.476-47.84 ± 2.814
Everyday Responsibilities: Week 12-2.98 ± 4.145-42.20 ± 3.363
Statistical analysis
  • Placebo vs Oveporexton · MMRM · p = <0.001 (The analysis used linear MMRM model.) · Ls mean difference: -40.77 · 95% CI -48.60 to -32.94
  • Placebo vs Oveporexton · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -30.17 · 95% CI -38.50 to -21.84
  • Placebo vs Oveporexton · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -19.1 · 95% CI -26.06 to -12.14
  • Placebo vs Oveporexton · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -36.11 · 95% CI -44.83 to -27.38
  • Placebo vs Oveporexton · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -41.17 · 95% CI -49.21 to -33.14
  • Placebo vs Oveporexton · MMRM · p = <0.001 (The analysis used a linear MMRM.) · Ls mean difference: -39.22 · 95% CI -48.82 to -29.62
SecondaryChange From Baseline to Week 12 in Short Form-36 Survey (SF-36) Mental and Physical Component Scores

The SF-36 is a 36-item, participant-reported survey of participant health that assesses the quality of life and includes both physical and mental components. It consists of 8 scaled scores (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health), which contribute variably to the physical and mental component summary scores. The component summary is scored based on a normal value of 50 based on US population average, with a normative range considered from 45-55. The lower the score the more disability. A positive change from baseline indicates an improvement, and a change greater than 3 points is considered minimally clinically meaningful. The linear MMRM was used for analysis.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Short Form-36 Survey (SF-36) Mental and Physical Component Scores
score on a scalePlaceboOveporexton
Physical Component Summary (PCS): Week 12-0.30 ± 1.0494.71 ± 0.854
Mental Component Summary (MCS): Week 12-0.86 ± 1.4318.45 ± 1.165
Statistical analysis
  • Placebo vs Oveporexton · MMRM · p = <0.001 (The analysis used linear MMRM model.) · Ls mean difference: 5.01 · 95% CI 2.55 to 7.46
  • Placebo vs Oveporexton · MMRM · p = <0.001 (The analysis used linear MMRM model.) · Ls mean difference: 9.32 · 95% CI 6.00 to 12.64
SecondaryNumber of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. A TEAE is defined as any event emerging or manifesting at or after the initiation of treatment with a study intervention or medicinal product or any existing event that worsens in either intensity or frequency following exposure to the study intervention or medicinal product.

Time frame:
Up to 16 weeks
Reported as:
Count of participants · Participants
Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsPlaceboOveporexton
Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)1560

Adverse events

Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/35 (0%)0/35 (0%)6/35 (17.1%)
Oveporexton0/70 (0%)0/70 (0%)56/70 (80%)
Most frequent other events
Most frequent other events
EventPlaceboOveporexton
PollakiuriaRenal and urinary disorders1/3543/70
InsomniaPsychiatric disorders1/3540/70
Micturition urgencyRenal and urinary disorders0/3510/70
Salivary hypersecretionGastrointestinal disorders0/355/70
GastroenteritisInfections and infestations2/352/70
HeadacheNervous system disorders2/353/70
RashSkin and subcutaneous tissue disorders0/354/70
Upper respiratory tract infectionInfections and infestations2/353/70

Baseline characteristics

The Full Analysis Set (FAS) consisted of all participants who were randomized.

Age, Continuous
Age, Continuous(years)PlaceboOveporextonTotal
Mean34.0 ± 13.1429.1 ± 9.6230.7 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOveporextonTotal
Female133750
Male223355
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOveporextonTotal
Hispanic or Latino000
Not Hispanic or Latino264268
Unknown or Not Reported92837
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboOveporextonTotal
American Indian or Alaska Native000
Asian71421
Native Hawaiian or Other Pacific Islander000
Black or African American000
White192847
More than one race000
Unknown or Not Reported92837
Mean Sleep Latency from the Maintenance of Wakefulness Test (MWT)
Mean Sleep Latency from the Maintenance of Wakefulness Test (MWT)(minutes)PlaceboOveporextonTotal
Mean4.1 ± 4.934.8 ± 4.904.5 ± 4.9
Epworth Sleepiness Scale (ESS) Total Score
Epworth Sleepiness Scale (ESS) Total Score(score on a scale)PlaceboOveporextonTotal
Mean17.9 ± 2.9517.3 ± 3.3817.5 ± 3.24
08

Study locations

28 sites
  • Takeda Site 1
    Glebe, New South Wales, Australia
  • Takeda Site 22
    Linz, 4020, Austria
  • Takeda Site 2
    Alken, Belgium
  • Takeda Site 3
    Erpent, 5101, Belgium
  • Takeda Site 25
    Ghent, 9000, Belgium
  • Takeda Site 24
    Leuven, 3000, Belgium
  • Takeda Site 23
    Liège, 4000, Belgium
  • Takeda Site 4
    Beijing, Beijing Municipality, China
  • Takeda Site 27
    Zhengzhou, Henan, China
  • Takeda Site 28
    Shanghai, Shanghai Municipality, China
  • Takeda Site 26
    Guangdong, China
  • Takeda Site 20
    Helsinki, 380, Finland
  • Takeda Site 21
    Tampere, 33520, Finland
  • Takeda Site 16
    Léon, Bordeaux 33076, France
  • Takeda Site 6
    Bron, France
  • Takeda Site 14
    Marseille, 13385, France
  • Takeda Site 5
    Montpellier, France
  • Takeda Site 15
    Nantes, 44093, France
  • Takeda Site 7
    Bologna, 40139, Italy
  • Takeda Site 17
    Pozzilli, 86077, Italy
  • Takeda Site 8
    Roma, Italy
  • Takeda Site 9
    Krakow, Poland
  • Takeda Site 11
    Seoul, Daegu 41931, South Korea
  • Takeda Site 10
    Suwon, Gyeonggi-do 16247, South Korea
  • Takeda Site 12
    Seoul, 3080, South Korea
  • 28003
    Barcelona, 08035, Spain
  • Takeda Site 13
    Madrid, Spain
  • Takeda Site 19
    Uppsala, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jun 2025, 7 months.

Results were first posted in Jul 2026, 1 year 1 month after primary completion.

Of 14 phase 3 interventional studies under Narcolepsy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2024
First posted
Jul 17, 2024
StartActual
Oct 8, 2024
Primary completionActual
Jun 4, 2025
CompletionActual
Jun 4, 2025
Results first posted
Jul 16, 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06505031
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jul 17, 2024
Start date
Oct 8, 2024
Primary completion
Jun 4, 2025
Completion
Jun 4, 2025
Results posted
Jul 16, 2026
Last update
Jul 16, 2026

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oveporexton

Start the discussion